Timothy Tyson is President at VALEANT PHARMACEUTICALS INTERNATIONAL (VRX). They have made 3 open-market trades across 3 companies since 2007, most recently 2024-06-05.
CIK 0001207405
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
2 open-market purchases totalling $114K since 2017, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SYRS | BUY | 2022-09-29 | 2022-10-03 | $6.26 | $106K | -1.3% | -32.1% | -43.5% |
| PrivateIcagen, Inc. | BUY | 2017-12-29 | 2018-01-02 | $0.37 | $8K | N/A | N/A | N/A |
| VRX | SELL | 2007-05-07 | 2007-06-06 | $16.47 | $5K | -12.8% | +0.4% | +0.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.